英文名稱 |
中文名稱 |
CAS號(hào) |
操作 |
RS1-PDK1 inhibitor |
N-(6-chloro-1,3-benzothiazol-2-yl)-1-benzothiophene-3-sulfonamide |
1643958-85-3 |
詳細(xì)
|
PDK1-IN-RS2 |
PDK1-IN-RS2 |
1643958-89-7 |
詳細(xì)
|
Eptinezumab |
依普奈珠單抗 |
1644539-04-7 |
詳細(xì)
|
TDRL-551 |
化合物 T28935 |
1644626-43-6 |
詳細(xì)
|
HTL14242 |
Benzonitrile, 3-chloro-5-[6-(5-fluoro-2-pyridinyl)-4-pyrimidinyl]- |
1644645-32-8 |
詳細(xì)
|
DA-6886 |
1645260-76-9 |
1645260-76-9 |
詳細(xì)
|
ACT-660602 |
化合物 ACT-660602 |
1646267-59-5 |
詳細(xì)
|
Tomuzotuximab |
Tomuzotuximab |
1646321-00-7 |
詳細(xì)
|
FD-IN-1 |
FD-IN-1 |
1646682-14-5 |
詳細(xì)
|
BTA-9881 |
化合物 T26914 |
1646857-24-0 |
詳細(xì)
|
(R)-AZD 9639 |
化合物 (R)-AZD 9639 |
1646857-28-4 |
詳細(xì)
|
Gimsilumab |
瑾司魯單抗 |
1648796-29-5 |
詳細(xì)
|
(Rac)-MEM 1003 |
3,5-Pyridinedicarboxylic acid, 4-(2-chloro-3-cyanophenyl)-1,4-dihydro-2,6-dimethyl-, 3-(2-methoxyethyl) 5-(1-methylethyl) ester |
165187-25-7 |
詳細(xì)
|
Fremanezumab |
瑞瑪奈珠單抗 |
1655501-53-3 |
詳細(xì)
|
NDB |
NDB |
1660153-08-1 |
詳細(xì)
|
Inotuzumab |
英妥珠單抗 |
1660159-36-3 |
詳細(xì)
|
BrBzGCp2 |
S-4-bromobenzylglutathione cyclopentyl diester |
166038-00-2 |
詳細(xì)
|
(Rac)-Naxifylline |
NAXIFYLLINE異構(gòu)體 |
166181-76-6 |
詳細(xì)
|
CRT-0105950 |
CRT-0105950
(CRT0105950) |
1661845-86-8 |
詳細(xì)
|
Parthenosin |
b-D-Glucopyranosiduronic acid,2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-1-benzopyran-3-yl, butyl ester |
166196-16-3 |
詳細(xì)
|
Flotetuzumab |
Flotetuzumab |
1664355-28-5 |
詳細(xì)
|
Timigutuzumab |
Timigutuzumab |
1665274-14-5 |
詳細(xì)
|
AGN 192870 |
化合物 AGN 192870 |
166977-57-7 |
詳細(xì)
|
CT-2584 |
1H-Purine-2,6-dione, 1-[11-(dodecylamino)-10-hydroxyundecyl]-3,7-dihydro-3,7-dimethyl- |
166981-13-1 |
詳細(xì)
|
Enrasentan |
1H-Indene-2-carboxylicacid,1-(1,3-benzodioxol-5-yl)-2,3-dihydro-3-[2-(2-hydroxyethoxy)-4-methoxyphenyl]-5-propoxy-,(1S,2R,3S)- |
167256-08-8 |
詳細(xì)
|
Relatlimab |
Relatlimab |
1673516-98-7 |
詳細(xì)
|
TGP-377/421 |
化合物 TGP-377/421 |
16752-89-9 |
詳細(xì)
|
Fluoroethylnormemantine |
FLUOROETHYLNORMEMANTINE |
1639210-26-6 |
詳細(xì)
|
Delmetacin |
地美辛 |
16401-80-2 |
詳細(xì)
|
Lupartumab |
Lupartumab |
1640971-88-5 |
詳細(xì)
|
TASP0390325 |
2-(3-Chloro-4-fluorophenyl)-N-(1-methylethyl)-6-[3-(4-morpholinyl)propoxy]-4-oxo-pyrido[2,3-d]pyrimidine-3(4H)-acetamide hydrochloride |
1642187-96-9 |
詳細(xì)
|
Leramistat |
HMC-C-01-A|||MBS2320 |
1642602-54-7 |
詳細(xì)
|
Zilovertamab |
澤羅妥單抗 |
1643432-38-5 |
詳細(xì)
|
PW0464 |
PW0464 |
1643462-93-4 |
詳細(xì)
|
SLMP53-1 |
化合物 SLMP53-1 |
1643469-17-3 |
詳細(xì)
|
Elsubrutinib |
ELSUBRUTINIB |
1643570-24-4 |
詳細(xì)
|
Frovocimab |
Frovocimab |
1643672-70-1 |
詳細(xì)
|
ZEN-3694 |
ZEN 3694 |
1643947-30-1 |
詳細(xì)
|
Talastine |
他拉斯汀 |
16188-61-7 |
詳細(xì)
|
Honokiol DCA |
Acetic acid, 2,2-dichloro-, 2'-[(2,2-dichloroacetyl)oxy]-3,5'-di-2-propen-1-yl[1,1'-biphenyl]-4-yl ester |
1620160-42-0 |
詳細(xì)
|
L-372662 |
化合物 T32497 |
162045-26-3 |
詳細(xì)
|
3-(Piperidin-4-yl)benzo[d]oxazol-2(3H)-one hydrochloride |
3-(哌啶-4-基)苯并[D]噁唑-2(3H)-酮鹽酸鹽 |
162045-54-7 |
詳細(xì)
|
GNE-8505 |
GNE-8505 |
1620573-48-9 |
詳細(xì)
|
TL4-12 |
化合物 T26280 |
1620820-12-3 |
詳細(xì)
|
Nav1.8-IN-4 |
2-(4-氟-2-甲基苯氧基)-N-(2-氧代-1,2-二氫吡啶-4-基)-4-(三氟甲基)苯甲酰胺 |
1620846-16-3 |
詳細(xì)
|
GPR81 agonist 1 |
化合物 GPR81 AGONIST 1 |
1620992-67-7 |
詳細(xì)
|
UCM-13207 |
化合物 UCM-13207 |
1621536-10-4 |
詳細(xì)
|
Clivatuzumab |
克利妥珠單抗 |
1622075-09-5 |
詳細(xì)
|
Selicrelumab |
塞魯單抗 |
1622140-49-1 |
詳細(xì)
|
Laprituximab |
Laprituximab |
1622327-38-1 |
詳細(xì)
|
Naratuximab |
那妥昔單抗 |
1622327-39-2 |
詳細(xì)
|
Zectivimod |
ZECTIVIMOD |
1623066-63-6 |
詳細(xì)
|
Glycopyrronium tosylate |
格隆銨甲苯磺酸鹽 |
1624259-25-1 |
詳細(xì)
|
Azido-PEG3-C6-Cl |
疊氮-三聚乙二醇-C6-氯 |
1625717-44-3 |
詳細(xì)
|
hTYR/AbTYR-IN-1 |
HTYR/ABTYR抑制劑1 |
1625821-37-5 |
詳細(xì)
|
Isolupalbigenin |
ISOLUPALBIGENIN |
162616-70-8 |
詳細(xì)
|
ABI-1968 |
1626364-18-8 |
1626364-18-8 |
詳細(xì)
|
(Rac)-Telinavir |
化合物 (RAC)-TELINAVIR |
162679-88-1 |
詳細(xì)
|
AC 7739 |
化合物 AC 7739 |
162705-22-8 |
詳細(xì)
|
Gü2602 |
化合物 Gü2602 |
1627094-88-5 |
詳細(xì)
|
JG-231 |
JG-231 |
1627126-59-3 |
詳細(xì)
|
Rivabazumab |
Rivabazumab |
1627519-84-9 |
詳細(xì)
|
TAK-020 |
化合物TAK-020 |
1627603-21-7 |
詳細(xì)
|
MLK-IN-1 |
N-(3,4-二甲氧基苯基)-3-(7-甲氧基苯并[B]噻吩-2-基)咪唑并[1,2-B]噠嗪-6-胺 |
1627729-62-7 |
詳細(xì)
|
Nerelimomab |
Nerelimomab [usan:inn] |
162774-06-3 |
詳細(xì)
|
CPL304110 |
化合物 CPL304110 |
1627826-19-0 |
詳細(xì)
|
FGFR4-IN-5 |
FGFR4-IN-5 |
1628793-01-0 |
詳細(xì)
|
GBT1118 |
化合物 GBT1118 |
1628799-51-8 |
詳細(xì)
|
Vobarilizumab |
Vobarilizumab |
1628814-88-9 |
詳細(xì)
|
Itacnosertib |
N4-([2,2-bipyridin]-3-yl)-N2-(3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)pyrimidine-2,4-diamine |
1628870-27-8 |
詳細(xì)
|
KZR-504 |
KZR-504 |
1629052-78-3 |
詳細(xì)
|
Ibiglustat succinate |
IBIGLUSTAT SUCCINATE |
1629063-80-4 |
詳細(xì)
|
Suptavumab |
Suptavumab |
1629615-23-1 |
詳細(xì)
|
ALDH2 modulator 1 |
ALDH2調(diào)節(jié)劑1 |
1629615-99-1 |
詳細(xì)
|
Suvratoxumab |
Suvratoxumab |
1629620-18-3 |
詳細(xì)
|
Ladiratuzumab |
LADIRATUZUMAB (ANTI-SLC39A6) |
1629760-28-6 |
詳細(xì)
|
Dalzanemdor |
化合物 DALZANEMDOR |
1629853-48-0 |
詳細(xì)
|
BDBM50597431 |
化合物BDBM50597431 |
1629853-49-1 |
詳細(xì)
|
(R)-DNMDP |
(R)-DNMDP |
1630760-60-9 |
詳細(xì)
|
URAT1 inhibitor 7 |
URAT1 INHIBITOR 7 |
1632002-28-8 |
詳細(xì)
|
Dapson-13C12 |
氨苯砜(13C12) |
1632119-29-9 |
詳細(xì)
|
Ranevetmab |
Ranevetmab |
1632282-27-9 |
詳細(xì)
|
DHODH-IN-17 |
化合物 DHODH-IN-17 |
16344-26-6 |
詳細(xì)
|
Talviraline |
HBY 097 |
163451-80-7 |
詳細(xì)
|
Aprutumab |
阿普盧妥單抗 |
1634620-63-5 |
詳細(xì)
|
Tavolixizumab |
Tavolimab |
1635395-25-3 |
詳細(xì)
|
Ralaniten triacetate |
RALANITEN TRIACETATE |
1637573-04-6 |
詳細(xì)
|
Cipepofol |
化合物 T32105 |
1637741-58-2 |
詳細(xì)
|
GS-626510 |
GS-626510 |
1637770-13-8 |
詳細(xì)
|
DI-82 |
DI-82 |
1638148-50-1 |
詳細(xì)
|
Osimertinib-d6 |
奧希替尼雜質(zhì)28 |
1638281-44-3 |
詳細(xì)
|
Otilimab |
對(duì)照抗體 |
1638332-55-4 |
詳細(xì)
|
Navicixizumab |
Navicixizumab |
1638338-43-8 |
詳細(xì)
|
VU0453379 |
VU0453379 |
1638646-27-1 |
詳細(xì)
|
Vonlerolizumab |
Vonlerolizumab |
1638935-72-4 |
詳細(xì)
|
MAO-B-IN-8 |
化合物 MAO-B-IN-8 |
1638956-60-1 |
詳細(xì)
|
Karavilagenin F |
Karavilagenin F |
1639024-15-9 |
詳細(xì)
|
pan-HER-IN-2 |
化合物 PAN-HER-IN-2 |
1639040-95-1 |
詳細(xì)
|
UniPR129 |
化合物 T26310 |
1639159-47-9 |
詳細(xì)
|
Fluoroethylnormemantine hydrochloride |
FLUOROETHYLNORMEMANTINE HYDROCHLORIDE |
1639210-25-5 |
詳細(xì)
|